Aravind Sugumar
University of Kansas
SurgeryPathologyOncologyIntensive care medicineImmunologyPancreatitisPresentation (obstetrics)Autoimmune pancreatitisPancreasDiseaseRare diseasePancreatic cancerAbdominal painPopulationCancer researchColorectal cancerGeneral surgeryMedicineBiologyGastroenterology
50Publications
17H-index
1,528Citations
Publications 50
Newest
#1Sivapriya Ponnurangam (KU: University of Kansas)H-Index: 9
#2Prasad Dandawate (KU: University of Kansas)H-Index: 21
Last. Dharmalingam SubramaniamH-Index: 25
view all 17 authors...
Cancer stem cells (CSCs) appear to explain many aspects of the neoplastic evolution of tumors and likely account for enhanced therapeutic resistance following treatment. Dysregulated Notch signaling, which affects CSCs plays an important role in pancreatic cancer progression. We have determined the ability of Quinomycin to inhibit CSCs and the Notch signaling pathway. Quinomycin treatment resulted in significant inhibition of proliferation and colony formation in pancreatic cancer cell lines, bu...
29 CitationsSource
#1Dharmalingam Subramaniam (KU: University of Kansas)H-Index: 25
#2Sivapriya Ponnurangam (KU: University of Kansas)H-Index: 9
Last. Shrikant Anant (KU: University of Kansas)H-Index: 40
view all 16 authors...
Background: Pancreatic cancer (PCa) remains a leading cause of death in the United States. Cancer stem cells (CSC) are responsible for tumor behavior, and therapeutic resistance. Quinomycin (Qui) is an orally administered quinoxaline antibiotic that bifunctionally intercalates with double stranded DNA. As a first step for repurposing this drug, we determined whether Qui affects PCa growth, and if so whether this is by suppressing stem cells. Method: Growth and apoptosis of PCa lines (MiaPaCa-2, ...
Source
#1Aravind Sugumar (Mayo Clinic)H-Index: 17
#2Santhi Swaroop Vege (Mayo Clinic)H-Index: 41
Source
#1Phil A. Hart (Mayo Clinic)H-Index: 25
#2Mark Topazian (Mayo Clinic)H-Index: 53
Last. Suresh T. Chari (Mayo Clinic)H-Index: 83
view all 14 authors...
Background There is a paucity of data on long-term management of type 1 autoimmune pancreatitis (AIP), a relapsing steroid-responsive disorder. Objective We describe our experience with treatment of relapses and maintenance of remission using steroid-sparing immunomodulators (IMs) and induction of remission using rituximab (RTX). Methods We obtained details of disease relapse and treatment in 116 type 1 AIP patients from clinic visits, medical records and telephone interviews. We compared relaps...
235 CitationsSource
#1Gokulakrishnan Balasubramanian (Mayo Clinic)H-Index: 7
#2Aravind Sugumar (Mayo Clinic)H-Index: 17
Last. Suresh T. Chari (Mayo Clinic)H-Index: 83
view all 13 authors...
Abstract Background Autoimmune pancreatitis (AIP) has been classified into type 1 and type 2 subtypes. Serum immunoglobulin G4 (IgG4) elevation characterizes type 1 AIP. Type 2 AIP and a subset of type 1 AIP are seronegative, i.e., have normal serum IgG4 levels. Aim We compared the profiles of the three subsets of AIP to identify the unique characteristics of seronegative type 1 AIP and type 2 AIP. Methods We compared the clinical profiles of 69 seropositive type 1 AIP patients, 21 seronegative ...
15 CitationsSource
Despite advances in molecular pathogenesis, pancreatic cancer remains a major unsolved health problem. It is a rapidly invasive, metastatic tumor that is resistant to standard therapies. The phosphatidylinositol-3-kinase (PI3K)/Akt and mammalian target of rapamycin (mTOR) signaling pathways are frequently dysregulated in pancreatic cancer. Gemcitabine (Gem) is the mainstay treatment for metastatic pancreatic cancer. P276 is a novel CDK inhibitor that induces G2/M arrest and inhibits tumor growth...
18 CitationsSource
#1Aravind SugumarH-Index: 17
Last. Shrikant AnantH-Index: 40
view all 5 authors...
Source
Autoimmune pancreatitis (AIP) is a unique form of corticosteroid responsive chronic pancreatitis. In recent years, a distinct clinical presentation, histology, serology, and subtypes of AIP have been identified. This rare form of chronic pancreatitis was probably first described by Henry Sarles in the 1960s. He described a type of sclerosing pancreatitis associated with hypergammaglobulinemia, which is very similar to the present-day description of AIP. The term autoimmune pancreatitis was not u...
17 CitationsSource
#1Aravind Sugumar (Mayo Clinic)H-Index: 17
#2Suresh T. Chari (Mayo Clinic)H-Index: 83
The purpose of this review is to provide a concise view of the existing knowledge of autoimmune pancreatitis (AIP) for practicing clinicians.AIP is a rare disease whose recognition and understanding are evolving.It is a type of chronic pancreatitis which often presents as obstructive jaundice,has a distinctive histology and is exquisitely sensitive to steroid therapy.This form of chronic pancreatitis has a unique clinical,biochemical,and radiological profile.The term “AIP” encompasses two subtyp...
28 CitationsSource
#1Seth Sweetser (Mayo Clinic)H-Index: 18
#2Aravind Sugumar (Mayo Clinic)H-Index: 17
Last. Lisa A. Boardman (Mayo Clinic)H-Index: 41
view all 3 authors...
2 CitationsSource